Barclays lowered the firm’s price target on Bruker (BRKR) to $46 from $50 and keeps an Overweight rating on the shares. The company’s guidance was cut but Barclays is confident in the second half ramp, the analyst tells investors in a research note. The firm says Bruker’s valuation is pricing in further earnings declines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker: Resilient Performance and Strategic Positioning Amidst 2025 Challenges
- Bruker Corporation Reports Strong Q1 2025 Revenue Growth
- Bruker Hold Rating: Balancing Optimism and Caution Amidst Uncertainties
- Bruker Corporation Navigates Growth Amidst Challenges
- Bruker reports Q1 EPS 47c, consensus 44c